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Abstract 30 
The widespread use of azole antifungals in medicine and agriculture and the resulting 31 
long-persistent residues could potentially affect beneficial fungi. However, there is very 32 
little information on the tolerance of non-target environmental fungi to azoles. In this 33 
study, we assessed the susceptibility of diverse plant- and insect-associated yeasts from 34 
the Metschnikowia clade, including several ecologically important species, to widely 35 
used medical and agricultural azoles (epoxiconazole, imazalil, ketoconazole and 36 
voriconazole). A total of 120 strains from six species were tested. Minimum inhibitory 37 
concentrations (MICs) were determined by the EUCAST broth microdilution procedure 38 
after some necessary modifications were made. The majority of species tested were 39 
highly susceptible to epoxiconazole, ketoconazole and voriconazole (>95% of strains 40 
showed MICs≤0.125 mg/l). Most strains were also very susceptible to imazalil, 41 
although MIC values were generally higher than for the other azoles. Furthermore, 42 
certain Metschnikowia reukaufii strains displayed a ‘trailing’ phenotype (i.e. showed 43 
reduced but persistent growth at antifungal concentrations above the MIC), but this 44 
characteristic was dependent on test conditions. It was concluded that exposure to 45 
azoles may pose a risk for ecologically relevant yeasts from the Metschnikowia clade, 46 
and thus could potentially impinge on the tripartite interaction linking these fungi with 47 
plants and their insect pollinators. 48 
49 
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Introduction 50 
Azoles are currently the largest and most widely used class of antifungal agents in 51 
clinical medicine (Sheehan et al. 1999; Pierce et al. 2013; Allen et al. 2015), and also 52 
represent a mainstay for crop protection and material preservation (Hof 2001; Groenier 53 
and Lebow 2006; Price et al. 2015). Their mechanism of action is mainly based on the 54 
alteration of cell membrane structure and function through interference with the 55 
biosynthesis of ergosterol, but alterations in nutrient transport and other pleiotropic 56 
effects not yet fully understood have also been described (Ghannoum and Rice 1999; 57 
Price et al. 2015; Sanguinetti et al. 2015).  58 
 Recently, azole resistance has been increasingly reported in many fungal 59 
pathogens of animals and plants, which is a cause of great public concern (Serfling et al. 60 
2007; Chakrabarti 2011; ECDC 2013; Vermeulen et al. 2013; Price et al. 2015). For 61 
some of such pathogens it has been suggested that antifungal resistance can arise during 62 
prolonged treatment or, alternatively, through exposure of the microorganism to sub-63 
lethal concentrations of the compounds in the environment (ECDC 2013). Moreover, 64 
azole residues can disperse and persist in the environment (Kahle et al. 2008; Battaglin 65 
et al. 2010; Bollmann et al. 2014) and potentially affect non-pathogenic or even 66 
beneficial fungi, and may therefore have a considerable impact on ecosystem health and 67 
functionality. However, there is very little information on the tolerance of non-target 68 
fungal species to medical and agricultural azoles, and risk assessments for antifungal 69 
use do not take into account their effects on entire fungal communities (Dijksterhuis et 70 
al. 2011; Dimitrov et al. 2014). 71 
 The Metschnikowia clade (Saccharomycetales) consists of an ancient and diverse 72 
group of ascomycetous yeasts harboring around 50 Metschnikowia species, the three 73 
species of genus Clavispora and several asexual forms currently assigned to the genus 74 
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Candida (Lachance 2011; Guzmán et al. 2013). Members of this clade are adapted to a 75 
wide variety of habitats, including flowers and their pollinators (e.g. Metschnikowia 76 
gruessii, M. proteae, and M. reukaufii), plant surfaces, fruits and agricultural soils (e.g. 77 
M. pulcherrima), and aquatic environments (e.g. M. bicuspidata) (Lachance 2011; 78 
Guzmán et al. 2013). Also, some Metschnikowia species are being used in agriculture 79 
since they are highly effective in the control of plant pathogens (Piano et al. 1997; 80 
Kurtzman and Droby 2001; Sipiczki 2006). The widespread presence of Metschnikowia 81 
species in natural and agricultural plant communities makes them a potential accidental 82 
target for azole antifungals. However, except for some reference strains from culture 83 
collections and a few clinical and agricultural isolates (Jawich et al. 2006; Desnos-84 
Ollivier et al. 2012; Savini et al. 2013; Cordero-Bueso et al. 2014), little is known about 85 
the possible effects that azoles might have on this ecologically important fungal group. 86 
 Floral nectar is a sugary solution essential for the attraction of pollinators that 87 
provide a key ecosystem service (Kearns et al. 1998; Vanbergen and the Insect 88 
Pollinators Initiative 2013). But nectar is also a crucial habitat for nectarivorous 89 
members of the Metschnikowia clade (Brysch-Herzberg 2004; Herrera et al. 2010), and 90 
this group of yeasts seems to play important ecological functions, including the 91 
attraction of pollinators (Herrera et al. 2013; Schaeffer and Irwin 2014; Schaeffer et al. 92 
2014; Pozo et al. 2015). It is well known that pesticides, chemical residues and azoles 93 
can accumulate in floral nectar and may have sublethal effects on plant pollinators 94 
(Rortais et al. 2005; Desneux et al. 2007; Wallner 2009; Blacquière et al. 2012; 95 
Bernauer et al. 2015). However, the impact of such anthropogenic contaminants on 96 
nectar yeast communities has not been investigated to date. 97 
In this study we determined the susceptibility of a large collection of strains 98 
from the Metschnikowia clade isolated from the floral nectar of diverse wild plants and 99 
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their insect pollinators to a number of azole antifungals that are widely used in 100 
agriculture (epoxiconazole and imazalil) and medicine (ketoconazole and voriconazole). 101 
Imazalil and ketoconazole are two imidazoles, i.e. compounds containing two nitrogen 102 
atoms in the azole ring, whereas epoxiconazole and voriconazole belong to the triazoles 103 
and have three nitrogen atoms in the azole ring (Sheehan et al. 1999). Minimum 104 
inhibitory concentrations (MICs) were determined by a modification of the reference 105 
European Committee on Antimicrobial Susceptibility Testing (EUCAST) broth 106 
microdilution (BMD) method. In addition, as antifungal susceptibility testing of yeasts 107 
from the Metschnikowia clade is still rarely performed, we explored the effect of some 108 
specific parameters (incubation time, MIC end point and culture medium) on the 109 
performance of the EUCAST method for this yeasts group.  110 
 111 
Materials and methods 112 
Isolates 113 
A total of 120 strains from the Metschnikowia clade, most of which were obtained and 114 
identified to the species level by molecular methods in the course of previous studies 115 
(Pozo et al. 2011, 2012; de Vega et al. 2012, 2014; Jacquemyn et al. 2013; Lenaerts et 116 
al. 2015), were tested (Table S1, supplementary materials). Studied strains belonged to 117 
the following six species: Metschnikowia reukaufii (n = 46), M. proteae (n = 23), M. 118 
gruessii (n = 22), M. koreensis (n = 11), M. caudata (n = 7) and Candida rancensis (n = 119 
11). Most strains originated from the floral nectar of wild plants (87.7% of total, 120 
excluding type strains) and insect floral visitors (12.3%) from South Africa (44.7%), 121 
Spain (36.0%), Morocco (10.5%) and Belgium (8.8%). In addition, the type strains of 122 
the six tested species were also included in the experiments (Table S1). All strains were 123 
stored at −80°C as cell suspensions in 25% glycerol stocks. 124 
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 125 
Antifungal susceptibility testing 126 
In vitro antifungal susceptibility of strains was determined by the reference EUCAST 127 
BMD procedure guidelines for yeasts (Arendrup et al. 2012), with some modifications 128 
in incubation conditions that had to be made for testing the strains investigated in this 129 
study (see below). RPMI 1640 (Sigma-Aldrich, Diegem, Belgium) supplemented with 130 
glucose (Sigma-Aldrich) to a final concentration of 20 g/l and buffered with 3-(N-131 
morpholino) propanesulfonic acid (Sigma-Aldrich) to a pH of 7.0 (hereafter referred to 132 
as RPMI+2%G) was used as test medium (Arendrup et al. 2012). The antifungal agents 133 
tested (all purchased from Sigma-Aldrich) were the imidazoles imazalil and 134 
ketoconazole, and the triazoles epoxiconazole and voriconazole. Final concentrations of 135 
the antifungal agents were in the range of 0.016 to 8 mg/l, and a positive control (i.e. 136 
drug-free medium) was included in each test. Assay plates (96 wells, flat-bottom; 137 
Thermo Fisher Scientific/Nunc, Roskilde, Denmark) were prepared in batches 138 
according to the EUCAST guidelines and stored until used (but always for less than 3 139 
months) at –80ºC. Prior to susceptibility testing, frozen strains were subcultured by at 140 
least two serial transfers on yeast malt (YM) agar (2.0% agar, 1.0% dextrose, 0.5% 141 
peptone, 0.3% yeast extract, 0.3% malt extract; pH 6.2) for 72 to 96 h at 25ºC, so as to 142 
check them for purity. Yeast suspensions were prepared in sterile distilled water, 143 
adjusted to the density of a 0.5 McFarland standard (1-5·106 cells/ml) and further 144 
diluted 1/10 in sterile distilled water. Columns 1 to 10 of the test plate contained 100 µl 145 
of twofold serial dilutions of the antifungals, column 11 contained 100 µl of drug-free 146 
medium, and column 12 corresponded to the sterility controls. One hundred microliters 147 
of the working yeast cell suspension were inoculated per well in columns 1 to 11, and 148 
100 µl of sterile distilled water per well in column 12. Plates were then covered with a 149 
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sterile lid to prevent the medium from evaporating and incubated at 25ºC. Although the 150 
EUCAST method recommends an incubation temperature of 35 ± 2ºC, we selected 25ºC 151 
as this is a common growth temperature for Metschnikowia species and most tested 152 
strains were unable to grow or only showed poor growth at 35 ± 2ºC (Lachance 2011; 153 
de Vega et al. 2012, 2014; Pozo et al. 2012). Assay plates were read 154 
spectrophotometrically (530 nm) after 24, 48 and 72 h of incubation. For the slow-155 
growing species M. caudata (de Vega et al. 2014), incubation was extended for 24 156 
additional hours (i.e. 96 h in total; see Results). All strains were tested at least twice on 157 
different days and Candida krusei ATCC 6258 and Candida parapsilosis ATCC 22019, 158 
which are two quality control strains recommended by the EUCAST method, were 159 
included in each series of experiments. Additionally, in order to assess possible 160 
differences in the performance of the EUCAST method related to the test medium, 161 
susceptibility tests were repeated for a selection of 37 strains (the seven M. caudata 162 
strains available, and six strains representative of different regions and/or hosts for each 163 
of the remaining five species) using non-synthetic YM broth (1.0% dextrose, 0.5% 164 
peptone, 0.3% yeast extract, 0.3% malt extract; pH 6.2) instead of synthetic 165 
RPMI+2%G.  166 
 167 
Data analysis 168 
Since no reference MIC end point has yet been established for susceptibility testing of 169 
azoles against Metschnikowia clade strains, end points of ≥50% and ≥90% of reduction 170 
in turbidity compared to the azole-free control well (i.e. partial and almost complete 171 
inhibition of growth, respectively) were determined. Essential agreement (EA) between 172 
the MIC values determined at different incubation times, or by using different test 173 
media (i.e. RPMI+2%G and YM broth) and reading end points (50% vs. 90%) was 174 
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defined as discrepancy of no more than ±2 two-fold dilutions (Cuenca-Estrella et al. 175 
2010). When necessary, high off-scale MIC results were converted to the next highest 176 
concentration and low off-scale MIC results were left unchanged (Pfaller et al. 2011). 177 
Discrepancies between MIC values were classified as non-substantial differences (NSD, 178 
discrepancies of three or four two-fold dilutions) or substantial differences (SD, 179 
discrepancies of >4 two-fold dilutions) (Cuenca-Estrella et al. 2010). Where relevant, 180 
differences among the MIC data distributions were evaluated by the Friedman’s test 181 
followed by Bonferroni post-hoc comparisons, as implemented in Statgraphics 182 
Centurion XVII (Statpoint Technologies, Inc., Warrenton, VA, USA). The critical p-183 
value was set at <0.05. 184 
 185 
Results 186 
Optimization of the EUCAST method for yeast strains from the Metschnikowia 187 
clade 188 
The EUCAST method for antifungal susceptibility testing recommends incubating 189 
microdilution plates for 24 ± 2 h, after which the absorbance at 530 nm of azole-free 190 
control wells should be >0.2 (Arendrup et al. 2012). If required, test plates can be 191 
further incubated for 12–24 h, but failure to reach the threshold absorbance after 48 h is 192 
considered to represent a failed test (Arendrup et al. 2012). A strict application of these 193 
stringent criteria was not possible in the present study, as most tested strains (including 194 
those used for quality control) displayed poor growth in RPMI+2%G medium after 24 h 195 
of incubation at 25ºC and, in some cases, an absorbance value >0.2 was not reached 196 
until 72 h (Figure 1). In addition, although all C. rancensis strains and the quality 197 
control strains displayed enough growth in RPMI+2%G after 48 h (Figure 1, Table 1 198 
and Table S2, supplementary materials), absorbance values for some strains were still 199 
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rather low (e.g. mean ± S.D. = 0.30 ± 0.02 for C. rancensis SA16, and 0.31 ± 0.03 for 200 
isolate SA25). Notably, none of the seven M. caudata isolates included in the study 201 
consistently grew in RPMI+2%G even after extended incubation up to 96 h post-202 
inoculum (Figure 1). 203 
In contrast, when tested in YM broth, the quality control strains and all strains 204 
tested except those belonging to M. caudata reached absorbance values >0.2 in just 24 h 205 
(Figure 1). Further incubation in YM broth resulted in most cases in saturated 206 
absorbance values in the drug-free wells (data not shown), thus resulting in unreliable 207 
MIC determination. For M. caudata, enough growth level for reliable MIC 208 
determination was not reached until 48–96 h, depending on the strain and test plate 209 
(Figure 1). 210 
Voriconazole MIC values obtained in RPMI+2%G medium for the quality 211 
control strains fell within the acceptable ranges provided in the EUCAST reference 212 
document (0.03–0.25 mg/l for C. krusei ATCC 6258 and 0.015–0.06 mg/l for C. 213 
parapsilosis ATCC 22019; Arendrup et al. 2012) or, for a minority of tests, differed in 214 
≤2 two-fold dilutions (Table 1; Table S2, supplementary materials). Obviously, due to 215 
the methodological modifications described in previous paragraphs, this comparison of 216 
voriconazole MICs for the quality control strains is tentative (the acceptable ranges 217 
given by the EUCAST document only refer to the 50% inhibition end point and 218 
incubation at 37ºC for 24 h). The reliability of epoxiconazole, imazalil and ketoconazole 219 
MIC determinations in RPMI+2%G could not be assessed, as acceptable MIC ranges 220 
are not yet available for these antifungals; nevertheless, repeated assays for these 221 
compounds yielded consistent results (data not shown). The same can be said for MIC 222 
determinations in YM broth. 223 
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In view of these results, it was concluded that for all species except M. caudata 224 
the optimal test conditions for azole MIC determination by the EUCAST procedure are 225 
72 h of incubation in RPMI+2%G or 24 h of incubation in YM broth. In the particular 226 
case of M. caudata, MIC values can only be reliably determined after 96 h of incubation 227 
in a nutrient rich medium such as YM broth. 228 
 229 
In vitro susceptibility to azole antifungals of yeasts of the Metschnikowia clade 230 
Table 2 shows the azole MIC distributions for the studied strains in RPMI +2%G 231 
medium (or YM broth, in the case of M. caudata). In general, epoxiconazole, 232 
ketoconazole and voriconazole were very active against all species tested and, 233 
regardless of the end point considered for MIC determination, >95% of strains were 234 
susceptible at concentrations ≤0.125 mg/l. Notably, in most cases there were no 235 
significant differences in the median MICs of epoxiconazole, ketoconazole and 236 
voriconazole (p >0.05 in all pair-wise comparisons except epoxiconazole vs. 237 
ketoconazole and epoxiconazole vs. voriconazole for M. reukaufii and the 90% 238 
inhibition end point). In contrast, median MICs for imazalil were generally higher (p 239 
<0.05 in all pair-wise comparisons except imazalil vs. voriconazole for M. caudata and 240 
the 90% inhibition end point), and MIC distributions depended largely on the species 241 
and endpoint criteria. For example, only 68.3% and 27.5% of the total number of 242 
isolates were susceptible to ≤0.125 mg/l of imazalil when the partial (≥50%) and almost 243 
complete (≥90%) inhibition end points were considered, respectively. 244 
An excellent EA (100%) was observed for most species-azole combinations 245 
between the MIC values obtained by the two end point criteria considered (Table 2). A 246 
notable exception was M. reukaufii, which yielded discrepant results for all tested 247 
antifungals: 1 NSD and 2 SD for epoxiconazole, 8 NSD for imazalil, and 1 SD for 248 
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ketoconazole and voriconazole (Table 2). Interestingly, one particular isolate (6.3.2-Y2, 249 
obtained in 2012 in Belgium from floral nectar of Pulmonaria officinalis) displayed 250 
discrepant results for all tested antifungals. In addition, two NSD were observed for M. 251 
caudata and imazalil. 252 
Regarding the comparison of test media, for most species, azole antifungal and 253 
end point combinations, the EA between the MIC results determined after 72 h of 254 
incubation in plates containing RPMI+2%G or 24 h in plates containing YM broth was 255 
100% (Table 3). Discrepancies in MIC results due to the test medium when the partial 256 
inhibition end point criterion was considered were only observed for imazalil and the 257 
species M. gruessii and M. koreensis, for which three out of the six isolates tested in 258 
each case yielded NSDs (Table 3). Non-significant differences were also obtained for 259 
the same three M. gruessii and a single M. reukaufii isolate when tested for imazalil 260 
susceptibility considering the almost complete inhibition end point (Table 3). Notably, 261 
isolate 6.3.2-Y2 of M. reukafii yielded SDs in the 90% end point MIC results when 262 
tested for epoxiconazole, ketoconazole and voriconazole susceptibility (Table 3). 263 
 264 
Discussion 265 
Controlling fungal pathogens is paramount to ensuring human and animal health, food 266 
security and preservation of wood and other materials (Hof 2001; ECDC 2013; Price et 267 
al. 2015). However, the widespread use of azole antifungals in agriculture and medicine 268 
is leading to a significant accumulation of azole residuals in the environment (Kahle et 269 
al. 2008; Battaglin et al. 2010), which poses a threat for the composition and/or 270 
functioning of fungal communities harboring non-target fungi (Dijksterhuis et al. 2011; 271 
Dimitrov et al. 2014). In spite of this, current knowledge about yeast antifungal 272 
susceptibility profiles is mostly limited to species responsible for human infections 273 
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(Desnos-Ollivier et al. 2012), and there is very scarce information on the tolerance of 274 
environmental fungi to antifungal compounds. To contribute to fill this research gap, 275 
this study has provided novel information on the azole susceptibility of plant- and 276 
insect-associated strains from the Metschnikowia clade. To do so, we first had to 277 
optimize the EUCAST broth microdilution method of antifungal susceptibility testing 278 
for Metschnikowia clade yeasts. 279 
Apart from setting the incubation temperature to 25ºC, which is optimal for 280 
members of the Metschnikowia clade (see Materials and Methods), the scarce growth 281 
displayed by most tested species in RPMI+2%G necessitated extended incubation of 282 
test plates (72 h, instead of the 24 h recommended by the EUCAST method) for reliable 283 
determination of azole MICs. Alternatively, adequate growth for MIC determination 284 
was obtained in just 24 h when RPMI+2%G was substituted for nutrient rich YM broth. 285 
Nevertheless, M. caudata was particularly recalcitrant to azole susceptibility testing, 286 
and MIC values for this species could only be determined when YM broth was used as 287 
test medium and plates were read after 96 h of incubation. 288 
In general, most strains included in the present study were highly susceptible to 289 
broad-spectrum imidazole and triazole antifungals of widespread use in clinical and 290 
agricultural settings. These findings are in line with the observation of Desnos-Ollivier 291 
et al. (2012), who tested 62 Metschnikowia isolates (belonging to 36 different species) 292 
from reference culture collections and found no resistance to the medical azoles 293 
fluconazole, itraconazole, posaconazole and voriconazole. Nevertheless, for a few M. 294 
reukaufii strains included in our study the azole MICs determined at a 90% inhibition 295 
end point were several two-fold dilutions higher than those obtained using the partial 296 
inhibition criterion. This observation points to the occurrence of a ‘trailing’ phenotype 297 
in some Metschnikowia strains, which is defined as the manifestation of reduced but 298 
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persistent growth in broth dilution tests with azole agents at antifungal concentrations 299 
above the MIC (Lee et al. 2004). Curiously, the trailing phenotype of M. reukaufii only 300 
appeared when susceptibility tests were performed in RPMI+2%G but not when these 301 
were carried out in YM broth, thus confirming that this effect depends on species and 302 
strain-specific characteristics, as well as on different methodological aspects 303 
(Arthington-Skaggs et al. 2002; Agrawal et al. 2007; Coenye et al. 2008). 304 
 It is worth noting that MICs for the imidazole imazalil for our strain collection 305 
were generally higher than those observed for the other azoles tested. A similar result 306 
was reported by Dijksterhuis et al. (2011) after performing toxicity tests to determine 307 
the effects of azoles and other fungicides on aquatic fungi and oomycetes. The reason 308 
for this higher susceptibility to imazalil is still unknown, but it might be due to a longer 309 
exposure to imazalil residues and/or the presence of higher concentrations of these in 310 
the environment. Indeed, imazalil has been extensively used in agriculture since the 311 
1970s, while epoxiconazole was introduced twenty years later (Morton and Staub 2008; 312 
Price et al. 2015). Typical uses of imazalil include field, glasshouse and indoor 313 
application by diverse methods (e.g. spraying, dipping, waxing) for the pre- and post-314 
harvest control of diverse fungal pathogens (EFSA 2010). Moreover, apart from its 315 
agricultural applications, imazalil is used (sometimes under the synonym enilconazole) 316 
in veterinary medicine as a topical broad-spectrum antimycotic and also in some 317 
countries as a fungicide formulation for the disinfection of farm buildings (EMEA 318 
1998), which constitute potential additional sources for environmental contamination 319 
(Kahle et al. 2008). Although most strains tested in this study were obtained from 320 
natural plant communities located relatively far from agricultural fields and human 321 
settlements, the presence of azole residues in these environments cannot be excluded 322 
and should be evaluated in future. 323 
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 Floral nectar is a valuable reward for pollinators, and extensive research work 324 
has been carried out to understand its composition, availability and secretion patterns 325 
(Nicolson and Thornburg 2007; Brandenburg et al. 2009; Heil 2011; Lievens et al. 326 
2015). More recently, there has been a growing interest in studying the role of floral 327 
nectar as a habitat for eukaryotic and prokaryotic microorganisms, and the effects these 328 
might have on nectar chemistry, pollinator behavior and sexual plant reproduction (see 329 
Pozo et al. 2015 for an updated review). In particular, it was found that Metschnikowia 330 
yeasts are widespread in the floral nectar of diverse plant families, and some species 331 
such as M. reukaufii could have a relevant role in attracting pollinators and influencing 332 
their foraging behaviour (Herrera et al. 2013; Schaeffer and Irwin 2014; Schaeffer et al. 333 
2014). Another emerging focus of interest is the study of the presence of anthropogenic 334 
contaminants in floral nectar, and the impact of these on declining pollinator 335 
populations and, eventually, on plant reproduction. For example, it has been that 336 
demonstrated that some insecticides such as the neonicotinoids are relatively common 337 
in nectar and can alter the physiology and behavior of pollinators (Blacquière et al. 338 
2012; Stanley et al. 2015). Although some studies have reported the presence of trace 339 
amounts of certain azoles in pollen and nectar collected by foraging honey bees shortly 340 
after field applications and over a prolonged time afterwards (e.g. Wallner 2009), to the 341 
best of our knowledge, no study has analyzed so far the possible effect of these 342 
antifungal compounds on the nectar microorganisms-plant-pollinator system. In any 343 
case, given the high susceptibility to azoles of nectar yeasts from the Metschnikowia 344 
clade found in this study, it seems clear that future risk assessments of the use of 345 
antifungals should pay attention to the nectar microbiota. 346 
 In summary, results of this study provide compelling evidence that exposure to 347 
azoles may pose a risk for ecologically important yeasts from the Metschnikowia clade, 348 
16 
 
and thus could potentially have detrimental effects on ecosystem dynamics and key 349 
services including plant pollination. This adds yet another source of concern for the 350 
long-term persistence of healthy plant-pollinator systems in natural communities. A 351 
next step would be to study the in planta effects of azoles on Metschnikowia yeasts, as 352 
well as to determine the actual ecological consequences of the in vitro results here 353 
reported. 354 
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Tables 
Table 1. Range of minimum inhibitory concentrations (MICs) obtained for quality control strains.
a 
Strain Test 
medium
b
 
Antifungal 
(n)
c
 
≥50% inhibition end point  ≥90% inhibition end point 
24 h 48 h 72 h  24 h 48 h 72 h 
Candida krusei 
ATCC 6258 
RPMI+2%G EPZ (23) ND(65.2%), 
≤0.016–0.125 
0.031–0.125 0.063–0.25  ND(65.2%), 
0.125–0.25 
0.25–0.5 0.5–1 
IZL (22) ND(54.5%), 
0.063–0.5 
0.5–2 1–4  ND(54.5%), 1–2 4 8 
KTZ (22) ND(63.6%), 
≤0.016–0.25 
0.031–0.25 0.063–0.25  ND(63.6%), 
0.25– 0.5 
0.5–1 0.5–1 
VCZ (22) ND(45.5%), 
0.031–0.125 
0.125–0.25 0.125–0.5  ND(45.5%), 0.25 0.25–0.5 0.5– 1 
YM broth EPZ (9) 0.125–0.25 1 1– 2  0.5 1–2 1–2 
IZL (10) 1–4 4–8 8–>8  2–8 4–8 8–>8 
KTZ (9) 0.25–1 0.5–2 0.5–4  0.5–2 0.5–2 0.5–4 
VCZ (9) 0.5 1–2 1–2  0.5–1 1–2 2 
Candida 
parapsilosis 
ATCC 22019 
RPMI+2%G EPZ (33) ND(45.5%), 
≤0.016– 0.031 
0.063–0.125 0.063–0.25  ND(45.5%), 
≤0.016–0.25 
0.25–0.5 0.25–0.5 
IZL (30) ND(36.7%), 
0.125–0.25 
0.25–0.5 0.5–1  ND(36.7%), 1–2 2–4 4–8 
KTZ (33) ND(36.4%), 
≤0.016–0.031 
≤0.016–0.031 ≤0.016–0.063  ND(36.4%), 
0.031–0.063 
0.063–0.125 0.125–0.25 
VCZ (33) ND(30.3%), 
≤0.016 
≤0.016–0.031 0.031  ND(30.3%), 
0.031–0.063 
0.031–0.063 0.063–0.125 
YM broth EPZ (8) 0.031–0.063 0.125–0.25 0.25–0.5  0.25 1 2–4 
IZL (6) 0.25– 1 1–4 2–8  1– 4 4–8 8–>8 
KTZ (7) ≤0.016 ≤0.016–0.063 0.031–0.125  ≤0.016–0.063 0.031–0.25 0.063– 1 
VCZ (8) 0.031 0.063 0.063– 0.125  0.063–0.125 0.125–0.25 0.25–0.5 
2 
 
a
 For each quality control strain and combination of test conditions (test medium, antifungal compound, incubation time –24, 48 and 72 h–, and 
inhibition end point), the range of MIC values (in mg/l) obtained in this study is given. In some cases, the percentage of tests in which the actual 
MIC value could not be determined (ND) due to scarce growth (i.e. absorbance at 530 nm ≤0.2; Arendrup et al. 2012) is also provided. 
b
 RPMI+2%G, RPMI 1640 supplemented with glucose and buffered with 3-(N-morpholino) propanesulfonic acid (see main text); YM broth, 
yeast malt broth. 
c
 EPZ, epoxiconazole; IZL, imazalil; KTZ, ketoconazole; VCZ, voriconazole. The number of tests performed (n) in each case is shown within 
parentheses. 
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Table 2. Distribution of minimum inhibitory concentrations (MICs) for azole antifungals determined by the EUCAST broth microdilution 
method for yeast strains of the Metschnikowia clade. 
Species (no. of 
strains tested) 
Antifungal
a
 End 
point
b
 
MIC distribution (mg/l)
c
 EA
d
 NSD
e
 SD
e
 
≤0.016 0.031 0.063 0.125 0.25 0.5 1 2 4 8 
Metschnikowia 
reukaufii (46) 
EPZ 50% 42* 3 1        93.5% 1 (2.2%) 2 (4.3%) 
90% 20 14* 7 2 1 1 1    
IZL 50% 1 2 2 22* 18 1     82.6% 8 (17.4%) 0 
90%   2 1 11 21* 11    
KTZ 50% 46*          97.8% 0 1 (2.2%) 
90% 39* 4 2     1   
VCZ 50% 46*          97.8% 0 1 (2.2%) 
90% 41* 3 1       1 
Metschnikowia 
proteae (23) 
EPZ 50% 23*          100% 0 0 
90% 23*          
IZL 50%   7 15* 1      100% 0 0 
90%    13* 10      
KTZ 50% 23*          100% 0 0 
90% 21* 2         
VCZ 50% 23*          100% 0 0 
90% 22* 1         
Metschnikowia 
gruessii (22) 
EPZ 50% 21*  1        100% 0 0 
90% 19* 2  1       
IZL 50%  1 16* 4   1    100% 0 0 
90%   1 14* 6   1   
KTZ 50% 21*  1        100% 0 0 
90% 21*   1       
VCZ 50% 21*  1        100% 0 0 
90% 20* 1   1      
Candida EPZ 50% 2 5* 4        100% 0 0 
4 
 
rancensis (11) 90% 1 2 5* 3       
IZL 50%    1 3 4* 3    100% 0 0 
90%     1 7*  2 1  
KTZ 50% 4 7*         100% 0 0 
90%  6* 4 1       
VCZ 50% 5 5* 1        100% 0 0 
90% 2 3 6*        
Metschnikowia 
koreensis (11) 
EPZ 50% 11*          100% 0 0 
90% 6* 4 1        
IZL 50%   1 7* 3      100% 0 0 
90%    2 2 7*     
KTZ 50% 9* 2         100% 0 0 
90% 8* 3         
VCZ 50% 10* 1         100% 0 0 
90% 9* 2         
Metschnikowia 
caudata
f
 (7) 
EPZ 50% 5* 2         100% 0 0 
90%  5* 2        
IZL 50%  1 1 1 2* 2     71.4% 2 (28.6%) 0 
90%      7*     
KTZ 50% 7*          100% 0 0 
90% 4* 3         
VCZ 50% 5* 2         100% 0 0 
90%  2 5*        
Total (120) EPZ 50% 104 
(86.7%) 
10 
(8.3%) 
6 (5%)        97.5% 1 (0.8%) 2 (1.7%) 
90% 69 
(57.5%) 
27 
(22.5%) 
15 
(12.5%) 
6 (5%) 1 
(0.8%) 
1 
(0.8%) 
1 
(0.8%) 
   
IZL 50% 1 
(0.8%) 
4 
(3.3%) 
27 
(22.5%) 
50 
(41.7%) 
27 
(22.5%) 
7 
(5.8%) 
4 
(3.3%) 
   91.7% 10 (8.3%) 0 
90%   3 
(2.5%) 
30 
(25%) 
30 
(25%) 
42 
(35%) 
11 
(9.2%) 
3 
(2.5%) 
1 
(0.8%) 
 
KTZ 50% 110 
(91.7%) 
9 
(7.5%) 
1 
(0.8%) 
       99.2% 0 1 (0.8%) 
5 
 
90% 93 
(77.5%) 
18 
(15%) 
6 (5%) 2 
(1.7%) 
   1 
(0.8%) 
  
VCZ 50% 110 
(91.7%) 
8 
(6.7%) 
2 
(1.7%) 
       99.2% 0 1 (0.8%) 
90% 94 
(78.3%) 
12 
(10%) 
12 
(10%) 
 1 
(0.8%) 
    1 
(0.8%) 
 
a
 EPZ, epoxiconazole; IZL, imazalil; KTZ, ketoconazole; VCZ, voriconazole.
  
b 
Percentage of growth inhibition relative to a positive control (i.e. test medium without azoles) set as end point for antifungal susceptibility 
testing. 
c
 Number (and percentage, only for total results) of strains falling into each MIC value. The median MIC value for each yeast species, antifungal 
and end point combination is indicated by an asterisk. 
d
 Percentage of essential agreement (i.e. discrepancy of no more than ±2 two-fold dilutions) between MIC values obtained for the different end 
points. 
e
 Number (and percentage) of strains showing non-substantial differences (NSDs) or substantial differences (SDs) between MIC values obtained 
for the different end points. 
f
 Azole susceptibility testing of Metschnikowia caudata strains was performed using yeast maltose (YM) broth instead of RPMI 1640 
supplemented with 2% (w/v) of glucose (RPMI+2%G) as culture medium and after 96 h of incubation at 25ºC instead of 72 h (see details in the 
main text). 
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Table 3. Comparison of the results obtained for a selection of yeast strains from the Metschnikowia clade when tested for azole susceptibility in 
different culture media. 
Species (no. of 
strains tested) 
Antifungal
a
 ≥50% inhibition end point  ≥90% inhibition end point 
MIC distribution
b
 %EA
c
 NSD
d
 SD
d
  MIC distribution
b
 %EA
c
 NSD
d
 SD
d
 
RPMI+2%G YM broth RPMI+2%G YM broth 
Candida 
rancensis (6) 
EPZ ≤0.016(1), 
0.031(3), 
0.063(2) 
0.031(2), 
0.063(3), 0.125(1) 
100 0 0  ≤0.016(1), 
0.063(3), 
0.125(2) 
0.031(1), 
0.063(1), 
0.125(3), 
0.25(1) 
100 0 0 
IZL 0.25(1), 
0.5(3), 1(2) 
1(2), 2(2), 4(2) 100 0 0  0.5(4), 2(1), 4(1) 1(1), 2(2), 4(1), 
8(1) 
100 0 0 
KTZ ≤0.016(2), 
0.031(4) 
0.031(2), 
0.063(2), 0.125(2) 
100 0 0  0.031(4), 
0.063(1), 
0.125(1) 
0.031(1), 
0.063(2), 
0.125(3) 
100 0 0 
VCZ ≤0.016(2), 
0.031(4) 
0.031(2), 
0.063(2), 0.125(2) 
100 0 0  ≤0.016(1), 
0.031(2), 
0.063(3) 
0.031(1), 
0.063(3), 
0.125(1), 
0.25(1) 
100 0 0 
Metschnikowia 
gruessii (6) 
EPZ ≤0.016(6) ≤0.016(5), 
0.031(1) 
100 0 0  ≤0.016(6) ≤0.016(3), 
0.031(2), 
0.063(1) 
100 0 0 
IZL 0.031(1), 
0.063(4), 
0.125(1) 
0.063(1), 
0.125(1), 0.25(1), 
0.5(2), 1(1) 
50 3 
(50%) 
0  0.125(5), 0.25(1) 0.125(1), 
0.25(1), 0.5(1), 
1(2), 2(1) 
50 3 (50%) 0 
KTZ ≤0.016(6) ≤0.016(5), 
0.031(1) 
100 0 0  ≤0.016(6) ≤0.016(4), 
0.031(2) 
100 0 0 
VCZ ≤0.016(6) ≤0.016(5), 
0.031(1) 
100 0 0  ≤0.016(6) ≤0.016(3), 
0.031(2), 
0.063(1) 
100 0 0 
Metschnikowia 
koreensis (6) 
EPZ ≤0.016(6) ≤0.016(1), 
0.031(5) 
100 0 0  ≤0.016(2), 
0.031(3), 
0.063(1) 
≤0.016(1), 
0.063(5) 
100 0 0 
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IZL 0.125(5), 
0.25(1) 
0.25(2), 0.5(1), 
1(3) 
50 3 
(50%) 
0  0.25(2), 0.5(4) 0.25(1), 0.5(1), 
1(4) 
100 0 0 
KTZ ≤0.016(4), 
0.031(2) 
≤0.016(2), 
0.031(4) 
100 0 0  ≤0.016(4), 
0.031(2) 
≤0.016(2), 
0.031(4) 
100 0 0 
VCZ ≤0.016(5), 
0.031(1) 
≤0.016(1), 
0.031(5) 
100 0 0  ≤0.016(5), 
0.031(1) 
0.031(2), 
0.063(4) 
100 0 0 
Metschnikowia 
proteae (6) 
EPZ ≤0.016(6) ≤0.016(6) 100 0 0  ≤0.016(6) ≤0.016(6) 100 0 0 
IZL 0.063(1), 
0.125(4), 
0.25(1) 
0.25(5), 0.5(1) 100 0 0  0.125(2), 0.25(4) 0.25(1), 0.5(5) 100 0 0 
KTZ ≤0.016(6) ≤0.016(6) 100 0 0  ≤0.016(5), 
0.031(1) 
≤0.016(5), 
0.031(1) 
100 0 0 
VCZ ≤0.016(6) ≤0.016(5), 
0.031(1) 
100 0 0  ≤0.016(6) ≤0.016(5), 
0.031(1) 
100 0 0 
Metschnikowia 
reukaufii (6) 
EPZ ≤0.016(6) ≤0.016(6) 100 0 0  ≤0.016(2), 
0.031(2), 
0.063(1), 1(1) 
≤0.016(1), 
0.031(4), 
0.063(1) 
83.3 0 1 
(16.7%) 
IZL 0.063(1), 
0.125(2), 
0.25(3) 
0.125(6) 100 0 0  0.25(2), 0.5(2), 
1(1), 2(2) 
0.125(4), 
0.25(1), 0.5(1) 
83.3 1 
(16.7%) 
0 
KTZ ≤0.016(6) ≤0.016(6) 100 0 0  ≤0.016(5), 2(1) ≤0.016(6) 83.3 0 1 
(16.7%) 
VCZ ≤0.016(6) ≤0.016(4), 
0.031(2) 
100 0 0  ≤0.016(5), 8(1) ≤0.016(1), 
0.031(5) 
83.3 0 1 
(16.7%) 
TOTAL (30) EPZ ≤0.016(25), 
0.031(3), 
0.063(2) 
≤0.016(18), 
0.031(8), 
0.063(3), 0.125(1) 
100 0 0  ≤0.016(17), 
0.031(5), 
0.063(5), 
0.125(2), 1(1) 
≤0.016(11), 
0.031(7), 
0.063(8), 
0.125(3), 
0.25(1) 
96.7 0 1 (3.3%) 
IZL 0.031(1), 
0.063(6), 
0.125(12), 
0.25(6), 
0.5(3), 1(2) 
0.063(1), 
0.125(7), 0.25(8), 
0.5(4), 1(6), 2(2), 
4(2) 
80 6 
(20%) 
0  0.125(7), 0.25(9), 
0.5(10), 1(1), 
2(2), 4(1) 
0.125(5), 
0.25(4), 0.5(8), 
1(8), 2(3), 4(1), 
8(1) 
86.7 4 
(13.3%) 
0 
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KTZ ≤0.016(24), 
0.031(6) 
≤0.016(19), 
0.031(7), 
0.063(2), 0.125(2) 
100 0 0  ≤0.016(20), 
0.031(7), 
0.063(1), 
0.125(1), 2(1) 
≤0.016(17), 
0.031(8), 
0.063(2), 
0.125(3) 
96.7 0 1 (3.3%) 
VCZ ≤0.016(25), 
0.031(5) 
≤0.016(15), 
0.031(11), 
0.063(2), 0.125(2) 
100 0 0  ≤0.016(23), 
0.031(3), 
0.063(3), 8(1) 
≤0.016(9), 
0.031(11), 
0.063(8), 
0.125(1), 
0.25(1) 
96.7 0 1 (3.3%) 
 
a
 EPZ, epoxiconazole; IZL, imazalil; KTZ, ketoconazole; VCZ, voriconazole.
  
b 
For each species and combination of test conditions (test medium, antifungal compound, and inhibition end point), the number of strains 
displaying each MIC value (in mg/l) is given. RPMI+2%G, RPMI 1640 supplemented with glucose and buffered with 3-(N-morpholino) 
propanesulfonic acid (see main text); YM broth, yeast malt broth. 
c
 Percentage of essential agreement (i.e. discrepancy of no more than ±2 two-fold dilutions) between MIC values obtained in different culture 
media. 
d
 Number (and percentage) of strains showing non-substantial differences (NSDs) or substantial differences (SDs) between MIC values obtained 
in different culture media. 
FIGURE LEGENDS 
Figure 1. Pie charts showing the percentages of isolates of the tested species which 
displayed enough growth for reliable azole susceptibility determination by the EUCAST 
method (i.e. absorbance at 530 nm >0.2 in the positive control well) at each reading 
time (24, 48 and 72 h for most species, and also 96 h for Metschnikowia caudata, see 
Results) in 100% (blue sectors), ≥75% but <100% (green),  ≥50% but <75% (orange), 
<50% but >0% (red) and 0% (black) of the test plates. Total numbers of isolates (N) and 
tests (n, mean ± S.D.) per species are as follows: i) experiments using RPMI-1640 
medium supplemented with 2% (w/v) glucose (RPMI+2%G): Metschnikowia reukaufii, 
N = 46, n = 423 (9.2 ± 1.6); M. proteae, N = 23, n = 193 (8.4 ± 0.7); M. gruessii, N = 
22, n = 181 (8.2 ± 0.8); M. koreensis, N = 11, n = 102 (9.3 ± 1.1); Candida rancensis, N 
= 11, n = 108 (9.8 ± 1.8); and M. caudata, N = 7, n = 56 (8 ± 0); ii) experiments using 
yeast malt (YM) broth: M. reukaufii, N = 6, n = 48 (8 ± 0); M. proteae, N = 6, n = 51 
(8.5 ± 1.1); M. gruessii, N = 6, n = 61 (10.2 ± 1.7); M. koreensis, N = 6, n = 66 (11 ± 
3.2); C. rancensis, N = 6, n = 52 (8.7 ± 1.5); and M. caudata, N = 7, n = 88 (12.6 ± 0.5). 
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Tables 
Table S1. Yeast strains included in the present study. 
Strain Yeast species Country of 
origin 
Habitat Host species (family) Year Reference
a
 
SA16 Candida rancensis South Africa Floral nectar Dierama trichorhizum (Iridaceae) 2008  
SA20 Candida rancensis South Africa Floral nectar Graderia scabra (Orobanchaceae) 2008  
SA25 Candida rancensis South Africa Floral nectar Kniphofia sp. (Xanthorrhoeaceae) 2008  
SA26 Candida rancensis South Africa Floral nectar Burchellia bubalina (Rubiaceae) 2008  
SA34 Candida rancensis South Africa Floral nectar Watsonia lepida (Iridaceae) 2008  
SA35-1 Candida rancensis South Africa Floral nectar Watsonia pillansii (Iridaceae) 2008  
SA40 Candida rancensis South Africa Floral nectar Haemanthus humilis (Amaryllidaceae) 2008  
SA45-1 Candida rancensis South Africa Floral nectar Protea caffra (Proteaceae) 2008  
SA71-2 Candida rancensis South Africa Floral nectar Adhatoda andromeda (Acanthaceae) 2008  
SA73-1 Candida rancensis South Africa Floral nectar Adhatoda andromeda (Acanthaceae) 2008  
NRRL Y-48759
T
 Candida rancensis USA Floral nectar Mimulus aurantiacus (Phrymaceae) 1984  
EBD-CdVSA08-1
T
 Metschnikowia caudata South Africa Floral nectar Protea dracomontana (Proteaceae) 2010 de Vega et al. 2014 
EBD-B8Y1 Metschnikowia caudata South Africa Floral nectar Apis mellifera (Apidae) 2010 de Vega et al. 2014 
EBD-CdVSA21-2 Metschnikowia caudata South Africa Floral nectar Protea roupelliae (Proteaceae) 2010 de Vega et al. 2014 
EBD-CdVSA23-1 Metschnikowia caudata South Africa Floral nectar Protea roupelliae (Proteaceae) 2010 de Vega et al. 2014 
EBD-CdVSA57-2AT Metschnikowia caudata South Africa Floral nectar Protea subvestita (Proteaceae) 2010 de Vega et al. 2014 
EBD-SA53 Metschnikowia caudata South Africa Floral nectar Protea roupelliae (Proteaceae) 2008 de Vega et al. 2014 
EBD-SA54 Metschnikowia caudata South Africa Floral nectar Protea roupelliae (Proteaceae) 2008 de Vega et al. 2014 
CBS 7657
T
 Metschnikowia gruessii Portugal Floral nectar Hebe salicifolia (Plantaginaceae) 1992  
6D1 Metschnikowia gruessii Spain Floral nectar Digitalis obscura (Plantaginaceae) 2009 Pozo et al. 2012 
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6D10 Metschnikowia gruessii Spain Floral nectar Digitalis obscura (Plantaginaceae) 2009 Pozo et al. 2012 
6D12 Metschnikowia gruessii Spain Floral nectar Digitalis obscura (Plantaginaceae) 2009 Pozo et al. 2012 
6E10 Metschnikowia gruessii Spain Floral nectar Gladiolus illyricus (Iridaceae) 2008 Pozo et al. 2011 
6E5 Metschnikowia gruessii Spain Floral nectar Lonicera implexa (Caprifoliaceae) 2008 Pozo et al. 2011 
6E6 Metschnikowia gruessii Spain Floral nectar Teucrium pseudochamaepytis 
(Lamiaceae) 
2008 Pozo et al. 2011 
6E8 Metschnikowia gruessii Spain Floral nectar Teucrium pseudochamaepytis 
(Lamiaceae) 
2008 Pozo et al. 2011 
6E9 Metschnikowia gruessii Spain Floral nectar Jasminum fruticans (Oleaceae) 2008 Pozo et al. 2011 
6F11 Metschnikowia gruessii Spain Floral nectar Antirrhinum australe (Plantaginaceae) 2008 Pozo et al. 2011 
6F12 Metschnikowia gruessii Spain Floral nectar Antirrhinum australe (Plantaginaceae) 2008 Pozo et al. 2011 
6F5 Metschnikowia gruessii Spain Floral nectar Digitalis obscura (Plantaginaceae) 2008 Pozo et al. 2011 
6F6 Metschnikowia gruessii Spain Floral nectar Digitalis obscura (Plantaginaceae) 2008 Pozo et al. 2011 
6F7 Metschnikowia gruessii Spain Floral nectar Digitalis obscura (Plantaginaceae) 2008 Pozo et al. 2011 
6F8 Metschnikowia gruessii Spain Floral nectar Phlomis lychnitis (Lamiaceae) 2008 Pozo et al. 2011 
6F9 Metschnikowia gruessii Spain Floral nectar Phlomis lychnitis (Lamiaceae) 2008 Pozo et al. 2011 
6G2 Metschnikowia gruessii Spain Floral nectar Prunella grandiflora (Lamiaceae) 2008 Pozo et al. 2011 
6G3 Metschnikowia gruessii Spain Floral nectar Prunella grandiflora (Lamiaceae) 2008 Pozo et al. 2011 
6G4 Metschnikowia gruessii Spain Floral nectar Prunella grandiflora (Lamiaceae) 2008 Pozo et al. 2011 
6G5 Metschnikowia gruessii Spain Floral nectar Atropa baetica (Solanaceae) 2008 Pozo et al. 2011 
6G6 Metschnikowia gruessii Spain Floral nectar Atropa baetica (Solanaceae) 2008 Pozo et al. 2011 
6G7 Metschnikowia gruessii Spain Floral nectar Atropa baetica (Solanaceae) 2008 Pozo et al. 2011 
CBS 8854T  Metschnikowia koreensis Korea Flower Lilium sp. (Liliaceae) 1999  
SA1-3 Metschnikowia koreensis South Africa Floral nectar Gladiolus longicollis (Iridaceae) 2008  
SA21 Metschnikowia koreensis South Africa Floral nectar Ruellia cordata (Acanthaceae) 2008  
SA41-1 Metschnikowia koreensis South Africa Floral nectar Stachys aethiopica (Lamiaceae) 2008  
SA44-1 Metschnikowia koreensis South Africa Floral nectar Ajuga ophrydis (Lamiaceae) 2008  
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SA60 Metschnikowia koreensis South Africa Floral nectar Glumicalyx goseloides 
(Scrophulariaceae) 
2008  
SA66 Metschnikowia koreensis South Africa Floral nectar Silene bellidioides (Caryophyllaceae) 2008  
SA70 Metschnikowia koreensis South Africa Floral nectar Disa crassicornis (Orchidaceae) 2008  
SA71-1 Metschnikowia koreensis South Africa Floral nectar Adhatoda andromeda (Acanthaceae) 2008  
SA8 Metschnikowia koreensis South Africa Floral nectar Gladiolus appendiculatus (Iridaceae) 2008  
SA9 Metschnikowia koreensis South Africa Floral nectar Dierama luteo-albidum (Iridaceae) 2008  
CdVSA78_2 Metschnikowia proteae South Africa Floral nectar Protea simplex (Proteaceae) 2010 de Vega et al. 2012 
EBDCdVSA 34_1 Metschnikowia proteae South Africa Floral nectar Protea caffra (Proteaceae) 2010 de Vega et al. 2012 
EBDCdVSA 35_1 Metschnikowia proteae South Africa Floral nectar Protea caffra (Proteaceae) 2010 de Vega et al. 2012 
EBDCdVSA 36_1 Metschnikowia proteae South Africa Floral nectar Protea caffra (Proteaceae) 2010 de Vega et al. 2012 
EBDCdVSA 37_1 Metschnikowia proteae South Africa Floral nectar Protea caffra (Proteaceae) 2010 de Vega et al. 2012 
EBDCdVSA 39_1 Metschnikowia proteae South Africa Floral nectar Protea caffra (Proteaceae) 2010 de Vega et al. 2012 
EBDCdVSA 46_1 Metschnikowia proteae South Africa Floral nectar Protea caffra (Proteaceae) 2010 de Vega et al. 2012 
EBDSA45_2 Metschnikowia proteae South Africa Floral nectar Protea caffra (Proteaceae) 2008 de Vega et al. 2012 
EBDT1Y1
T
 Metschnikowia proteae South Africa Insect 
(Coleoptera) 
Trichostetha fascicularis 
(Scarabaeidae: Cetoniinae) 
2008 de Vega et al. 2012 
EBDC2Y2
AT
  Metschnikowia proteae South Africa Insect 
(Coleoptera) 
Cyrtothyrea marginalis (Scarabaeidae: 
Cetoniinae) 
2008 de Vega et al. 2012 
EBDA10Y1 Metschnikowia proteae South Africa Insect 
(Coleoptera) 
Atrichelaphinis tigrina (Scarabaeidae: 
Cetoniinae) 
2008 de Vega et al. 2012 
EBDA7Y1 Metschnikowia proteae South Africa Insect 
(Coleoptera) 
Atrichelaphinis tigrina (Scarabaeidae: 
Cetoniinae) 
2008 de Vega et al. 2012 
EBDC1Y3 Metschnikowia proteae South Africa Insect 
(Coleoptera) 
Cyrtothyrea marginalis (Scarabaeidae: 
Cetoniinae) 
2008 de Vega et al. 2012 
EBDC3Y1 Metschnikowia proteae South Africa Insect 
(Coleoptera) 
Cyrtothyrea marginalis (Scarabaeidae: 
Cetoniinae) 
2008 de Vega et al. 2012 
EBDC4Y1 Metschnikowia proteae South Africa Insect Cyrtothyrea marginalis (Scarabaeidae: 2008 de Vega et al. 2012 
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(Coleoptera) Cetoniinae) 
EBDM1Y1 Metschnikowia proteae South Africa Insect 
(Coleoptera) 
Heterochelus sp. (Scarabaeidae: 
Hopliinae) 
2008 de Vega et al. 2012 
EBDM2Y1 Metschnikowia proteae South Africa Insect 
(Coleoptera) 
Heterochelus sp. (Scarabaeidae: 
Hopliinae) 
2008 de Vega et al. 2012 
EBDM3Y1 Metschnikowia proteae South Africa Insect 
(Coleoptera) 
Heterochelus sp. (Scarabaeidae: 
Hopliinae) 
2008 de Vega et al. 2012 
EBDM6Y1 Metschnikowia proteae South Africa Insect 
(Coleoptera) 
Heterochelus sp. (Scarabaeidae: 
Hopliinae) 
2008 de Vega et al. 2012 
EBDM7Y1 Metschnikowia proteae South Africa Insect 
(Coleoptera) 
Heterochelus sp. (Scarabaeidae: 
Hopliinae) 
2008 de Vega et al. 2012 
EBDT2Y1 Metschnikowia proteae South Africa Insect 
(Coleoptera) 
Trichostetha fascicularis 
(Scarabaeidae: Cetoniinae) 
2008 de Vega et al. 2012 
EBDF1Y1 Metschnikowia proteae South Africa Insect (Diptera) Drosophilidae sp. 2008 de Vega et al. 2012 
EBDF2Y1 Metschnikowia proteae South Africa Insect (Diptera) Drosophilidae sp. 2008 de Vega et al. 2012 
ST12.14/017 Metschnikowia reukauffi Belgium Floral nectar Symphytum officinale (Boraginaceae) 2013 Lenaerts et al. 2015 
ST12.14/020 Metschnikowia reukauffi Belgium Floral nectar Symphytum officinale (Boraginaceae) 2013 Lenaerts et al. 2015 
7.3K/FT9 A Metschnikowia reukaufii Belgium Floral nectar Pulmonaria officinalis (Boraginaceae) 2012 Jacquemyn et al. 2013 
7.8L/FT6 Metschnikowia reukaufii Belgium Floral nectar Pulmonaria officinalis (Boraginaceae) 2012 Jacquemyn et al. 2013 
7.9L/FT9 A Metschnikowia reukaufii Belgium Floral nectar Pulmonaria officinalis (Boraginaceae) 2012 Jacquemyn et al. 2013 
ST12.14/023 Metschnikowia reukaufii Belgium Floral nectar Symphytum officinale (Boraginaceae) 2013 Lenaerts et al. 2015 
ST12.14/029 Metschnikowia reukaufii Belgium Floral nectar Symphytum officinale (Boraginaceae) 2013 Lenaerts et al. 2015 
ST12.14/030 Metschnikowia reukaufii Belgium Floral nectar Symphytum officinale (Boraginaceae) 2013 Lenaerts et al. 2015 
ST12.14/496 Metschnikowia reukaufii Belgium Floral nectar Symphytum officinale (Boraginaceae) 2013 Lenaerts et al. 2015 
6.3.2-Y2 Metschnikowia reukaufii Belgium Floral nectar Pulmonaria officinalis (Boraginaceae) 2012 Jacquemyn et al. 2013 
CECT 10671
T
 Metschnikowia reukaufii Canada Flower Epilobium angustifolium (Onagraceae) 1968  
CdV Mar10.1 Metschnikowia reukaufii Morocco Floral nectar Nonea vesicaria (Boraginaceae) 2013  
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CdV Mar11.1 Metschnikowia reukaufii Morocco Floral nectar Nonea vesicaria (Boraginaceae) 2013  
CdV Mar13.1 Metschnikowia reukaufii Morocco Floral nectar Teucrium pseudochamaepitys 
(Lamiaceae) 
2013  
CdV Mar16.1 Metschnikowia reukaufii Morocco Floral nectar Lamium album (Lamiaceae) 2013  
CdV Mar17.1 Metschnikowia reukaufii Morocco Floral nectar Lavandula multifida (Lamiaceae) 2013  
CdV Mar21.1 Metschnikowia reukaufii Morocco Floral nectar Lavandula multifida (Lamiaceae) 2013  
CdV Mar31.1 Metschnikowia reukaufii Morocco Floral nectar Gladiolus italicus-communis 
(Iridaceae) 
2013  
CdV Mar33.1 Metschnikowia reukaufii Morocco Floral nectar Gladiolus italicus-communis 
(Iridaceae) 
2013  
CdV Mar34.1 Metschnikowia reukaufii Morocco Floral nectar Gladiolus italicus-communis 
(Iridaceae) 
2013  
CdV Mar4.1 Metschnikowia reukaufii Morocco Floral nectar Linaria sp. (Plantaginaceae) 2013  
CdV Mar8.1 Metschnikowia reukaufii Morocco Floral nectar Echium plantagineum (Boraginaceae) 2013  
CdV Mar9.1 Metschnikowia reukaufii Morocco Floral nectar Nonea vesicaria (Boraginaceae) 2013  
SA33 Metschnikowia reukaufii South Africa Floral nectar Gladiolus parvulus (Iridaceae) 2008  
SA44-2 Metschnikowia reukaufii South Africa Floral nectar Ajuga ophrydis (Lamiaceae) 2008  
SA72-1 Metschnikowia reukaufii South Africa Floral nectar Adhatoda andromeda (Acanthaceae) 2008  
1A2 Metschnikowia reukaufii Spain Floral nectar Helleborus foetidus (Ranunculaceae) 2009  
1B11 Metschnikowia reukaufii Spain Floral nectar Aquilegia vulgaris (Ranunculaceae) 2008 Pozo et al. 2011 
1B4 Metschnikowia reukaufii Spain Floral nectar Anthyllis vulneraria (Fabaceae) 2008 Pozo et al. 2011 
1B5 Metschnikowia reukaufii Spain Floral nectar Tetragonolobus maritimus (Fabaceae) 2008 Pozo et al. 2011 
1B7 Metschnikowia reukaufii Spain Floral nectar Aquilegia vulgaris (Ranunculaceae) 2008 Pozo et al. 2011 
1C5 Metschnikowia reukaufii Spain Floral nectar Tetragonolobus maritimus (Fabaceae) 2008 Pozo et al. 2011 
1D6 Metschnikowia reukaufii Spain Floral nectar Tetragonolobus maritimus  (Fabaceae) 2008 Pozo et al. 2011 
2C12 Metschnikowia reukaufii Spain Floral nectar Iris foetidissima (Iridaceae) 2008 Pozo et al. 2011 
2C2 Metschnikowia reukaufii Spain Floral nectar Vicia onobrychioides (Fabaceae) 2008 Pozo et al. 2011 
2D10 Metschnikowia reukaufii Spain Floral nectar Prunella grandiflora (Lamiaceae) 2008 Pozo et al. 2011 
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2D11 Metschnikowia reukaufii Spain Floral nectar Prunella grandiflora (Lamiaceae) 2008 Pozo et al. 2011 
2D6 Metschnikowia reukaufii Spain Floral nectar Vicia villosa (Fabaceae) 2008 Pozo et al. 2011 
2D7 Metschnikowia reukaufii Spain Floral nectar Vicia villosa (Fabaceae) 2008 Pozo et al. 2011 
2E2 Metschnikowia reukaufii Spain Floral nectar Aquilegia pyrenaica cazorlensis 
(Ranunculaceae) 
2008 Pozo et al. 2011 
2E3 Metschnikowia reukaufii Spain Floral nectar Aquilegia pyrenaica cazorlensis 
(Ranunculaceae) 
2008 Pozo et al. 2011 
2E4 Metschnikowia reukaufii Spain Floral nectar Aquilegia pyrenaica cazorlensis 
(Ranunculaceae) 
2008 Pozo et al. 2011 
3A3 Metschnikowia reukaufii Spain Floral nectar Helleborus foetidus (Ranunculaceae) 2008 Pozo et al. 2011 
3B10 Metschnikowia reukaufii Spain Floral nectar Helleborus foetidus (Ranunculaceae) 2008 Pozo et al. 2011 
3C12 Metschnikowia reukaufii Spain Floral nectar Helleborus foetidus (Ranunculaceae) 2008 Pozo et al. 2011 
5C4 Metschnikowia reukaufii Spain Floral nectar Helleborus foetidus (Ranunculaceae) 2008 Pozo et al. 2011 
 
T
, type strain; AT, allotype strain. 
a
 When relevant, references for field-collected strains are provided (see details in the References section of the paper).
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Table S2. Distribution of minimum inhibitory concentrations (MICs, in mg/l) obtained for quality control strains.
a
 
Strain Test 
medium
b
 
Antifungal 
(n)
c
 
≥50% inhibition end point  ≥90% inhibition end point 
24 h 48 h 72 h  24 h 48 h 72 h 
Candida krusei 
ATCC 6258 
RPMI+2%G EPZ (23) ND(65.2%), 
≤0.016(13%), 
0.031(17.4%), 
0.125(4.3%) 
0.031(8.7%), 
0.063(60.9%), 
0.125(30.4%) 
0.063(4.3%), 
0.125(73.9%), 
0.25(21.7%) 
 ND(65.2%), 
0.125(17.4%), 
0.25 (17.4%) 
0.25(21.7%), 
0.5(78.3%) 
0.5(30.4%), 
1(69.6%) 
IZL (22) ND(54.5%), 
0.063(4.5%), 
0.125(4.5%), 
0.25(13.6%), 
0.5(22.7%) 
0.5(22.7%), 
1(63.6%), 
2(13.6%) 
1(4.5%), 
2(86.4%), 
4(9.1%) 
 ND(54.5%), 
1(13.6%), 
2(31.8%) 
4(100%) 8(100%) 
KTZ (22) ND(63.6%), 
≤0.016(4.5%), 
0.031(4.5%), 
0.125(18.2%), 
0.25(9.1%) 
0.031(9.1%), 
0.063(22.7%), 
0.125(59.1%), 
0.25(9.1%) 
0.063(18.2%), 
0.125(59.1%), 
0.25(22.7%) 
 ND(63.6%), 
0.25(13.6%), 
0.5(22.7%) 
0.5(90.9%), 1(9.1%) 0.5(22.7%), 
1(77.3%) 
VCZ (22) ND(45.5%), 
0.031(4.5%), 
0.063(27.3%), 
0.125(22.7%) 
0.125(72.7%), 
0.25(27.3%) 
0.125(9.1%), 
0.25(86.4%), 
0.5(4.5%) 
 ND(45.5%), 
0.25(54.5%) 
0.25(4.5%), 
0.5(95.5%) 
0.5(86.4%), 
1(13.6%) 
YM broth EPZ (9) 0.125(33.3%), 
0.25(66.7%) 
1(100%) 1(55.6%), 
2(44.4%) 
 0.5(100%) 1(77.8%), 2(22.2%) 1(33.3%), 
2(66.7%) 
IZL (10) 1(10%), 
2(30%), 4(60%) 
4(40%), 8(60%) 8(70%), 
>8(30%) 
 2(10%), 4(80%), 
8(10%) 
4(10%), 8(90%) 8(40%), 
>8(60%) 
KTZ (9) 0.25(33.3%), 
1(66.7%) 
0.5(33.3%), 
2(66.7%) 
0.5(22.2%), 
1(11.1%), 
2(55.6%), 
4(11.1%) 
 0.5(33.3%), 
1(55.6%), 
2(11.1%) 
0.5(22.2%), 
1(11.1%), 2(66.7%) 
0.5(11.1%), 
1(11.1%), 
2(11.1%), 
4(66.7%) 
VCZ (9) 0.5(100%) 1(88.9%), 
2(11.1%) 
1(33.3%), 
2(66.7%) 
 0.5(11.1%), 
1(88.9%) 
1(55.6%), 2(44.4%) 2(100%) 
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Candida 
parapsilosis 
ATCC 22019 
RPMI+2%G EPZ (33) ND(45.5%), 
≤0.016(9.1%), 
0.031(45.5%) 
0.063(66.7%), 
0.125(33.3%) 
0.063(3%), 
0.125(93.9%), 
0.25(3%) 
 ND(45.5%), 
≤0.016(3%), 
0.125(48.5%), 
0.25(3%) 
0.25(93.9%), 
0.5(6.1%) 
0.25(24.2%), 
0.5(75.8%) 
IZL (30) ND(36.7%), 
0.125(20%), 
0.25(43.3%) 
0.25(13.3%), 
0.5(86.7%) 
0.5(36.7%), 
1(63.3%) 
 ND(36.7%), 
1(56.7%), 
2(6.7%) 
2(30%), 4(70%) 4(86.7%), 
8(13.3%) 
KTZ (33) ND(36.4%), 
≤0.016(60.6%), 
0.031(3%) 
≤0.016(33.3%), 
0.031(66.7%) 
≤0.016(3%), 
0.031(90.9%), 
0.063(6.1%) 
 ND(36.4%), 
0.031(3%), 
0.063(60.6%) 
0.063(9.1%), 
0.125(90.9%) 
0.125(90.9%), 
0.25(9.1%) 
VCZ (33) ND(30.3%), 
≤0.016(69.7%) 
≤0.016(33.3%), 
0.031(66.7%) 
0.031(100%)  ND(30.3%), 
0.031(63.6%), 
0.063(6.1%) 
0.031(6.1%), 
0.063(93.9%) 
0.063(90.1%), 
0.125(9.1%) 
YM broth EPZ (8) 0.031(25%), 
0.063(75%) 
0.125(87.5%), 
0.25(12.5%) 
0.25(25%), 
0.5(75%) 
 0.25(100%) 1(100%) 2(75%), 4(25%) 
IZL (6) 0.25(33.3%), 
0.5(33.3%), 
1(33.3%) 
1(33.3%), 
2(16.7%), 
4(50%) 
2(33.3%), 
8(66.7%) 
 1(16.7%), 
2(50%), 
4(33.3%) 
4(33.3%), 8(66.7%) 8(50%), 
>8(50%) 
KTZ (7) ≤0.016(100%) ≤0.016(42.9%), 
0.063(57.1%) 
0.031(42.9%), 
0.125(57.1%) 
 ≤0.016(14.3%), 
0.031(28.6%), 
0.063(57.1%) 
0.031(14.3%), 
0.063(28.6%), 
0.125(42.9%), 
0.25(14.3%) 
0.063(14.3%), 
0.125(14.3%), 
0.25(42.9%), 
0.5(14.3%), 
1(14.3%) 
VCZ (8) 0.031(100%) 0.063(100%) 0.063(12.5%), 
0.125(87.5%) 
 0.063(37.5%), 
0.125(62.5%) 
0.125(12.5%), 
0.25(87.5%) 
0.25(25%), 
0.5(75%) 
 
a
 For each quality control strain and combination of test conditions (test medium, antifungal compound, incubation time –24, 48 and 72 h–, and 
inhibition end point), the percentage of tests in which each MIC value was obtained is given within parentheses. In some cases, the actual MIC 
value could not be determined (ND) due to scarce growth (i.e. absorbance at 530 nm ≤0.2; Arendrup et al. 2012). 
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b
 RPMI+2%G, RPMI 1640 supplemented with glucose and buffered with 3-(N-morpholino) propanesulfonic acid (see main text); YM broth, 
yeast malt broth. 
c
 EPZ, epoxiconazole; IZL, imazalil; KTZ, ketoconazole; VCZ, voriconazole. The number of tests performed (n) in each case is shown within 
parentheses. 
